CYRAMZA may help starve cancerous tumors
As an anti-angiogenic, CYRAMZA works differently from traditional chemotherapy or targeted therapy. Depending on what type of metastatic NSCLC you have, CYRAMZA may be used in combination with either your chemotherapy or the targeted therapy, erlotinib, to help fight your metastatic NSCLC.*
CYRAMZA may work as a tumor-starving agent to attack your cancer. Tumors need nutrients to grow, which are mainly supplied through your blood vessels. CYRAMZA is thought to stop new blood vessels from forming, including those that feed your tumor. This may help starve the tumor of the nutrients it needs to keep growing.
See below for how CYRAMZA is thought to work.
CYRAMZA was shown to interfere with angiogenesis which may slow tumor growth*
*The process of how CYRAMZA is thought to work was shown in laboratory studies.
- Tumor sends out signals to certain receptors asking cells to build new blood vessels
- Receptors receive the signals
- Development of new blood vessels begins, which may mean more nutrients for your tumor